SCHEMBL5885763

SCHEMBL5885763

CC(=O)C1(Nc2ccc(C#CCNc3cccc(C#N)c3)cc2C)CCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.40
TSHR P16473 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 2/20 0.38
ALDH1A1 P00352 4/20 0.38
MAPT P10636 2/20 0.38
HSD17B10 Q99714 1/20 0.37
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
MAPK1 P28482 1/20 0.35
ICMT O60725 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5885830 0.84 ITGB3 (0.34) CYP1A2ALDH1A1CYP3A4
SCHEMBL5885802 0.83 PPARG (0.34) HIF1ATSHRCYP1A2CYP2D6ALDH1A1
SCHEMBL5885749 0.74 ACACB (0.48) HIF1ATSHRCYP1A2CYP2D6ALDH1A1
SCHEMBL5885765 0.73 LMNA (0.45) TSHRCYP2D6ALDH1A1MAPTKMT2A
SCHEMBL5885707 0.72 ACACB (0.38) HIF1ATSHRCYP1A2CYP2D6ALDH1A1
SCHEMBL6989644 0.70 ALDH1A1 (0.51) HIF1ATSHRCYP1A2CYP2D6ALDH1A1
SCHEMBL5885046 0.69 CYP3A4 (0.49) HIF1ATSHRCYP1A2CYP2D6ALDH1A1
SCHEMBL6991463 0.69 TSHR (0.51) HIF1ATSHRCYP1A2CYP2D6ALDH1A1
SCHEMBL5885577 0.68 ALDH1A1 (0.49) HIF1ATSHRALDH1A1MAPTHSD17B10
SCHEMBL5886021 0.65 CCKBR (0.42) HIF1ATSHRCYP1A2CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7005437-B2 Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2006-02-28 US disclosed
US-20030045712-A1 Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045712-A1 Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions F2, F12, F3 HIF1A 834/4885TSHR 576/4885CYP1A2 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.